Pancreatic Cancer | Oncology Today with Dr Neil Love: PARP Inhibition in the Management of Pancreatic Cancer Edition

Featuring an interview with Dr Kim Reiss Binder on recent advances in the use of PARP inhibitors in pancreatic cancer, including the following topics: PARP inhibitors in pancreatic cancer — Kim Reiss Binder, MD (00:00) Case: A man in his late 50s with metastatic pancreatic adenocarcinoma and a germline BRCA2 mutation attains a good response to maintenance olaparib after treatment with platinum-based chemotherapy (32:40) Case: A man in his early 50s with metastatic pancreatic adenocarcinoma and a PALB2 mutation receives maintenance rucaparib on a clinical trial (37:54) Case: A woman in her late 50s with metastatic pancreatic adenocarcinoma experiences a complete response to the combination of niraparib and ipilimumab on the Parpvax trial after receiving chemotherapy (41:59) CME information and select publications